Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: A meta-analysis of response, toxicity, and survival

Cancer

Volumn 82, Issue 1, 1998, Pages 116-126

  Lilenbaum, Rogerio C ^a,b,d   Langenberg, Patricia ^c   Dickersin, Kay ^c  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d Miami Beach FL   (United States)

Author keywords

Meta analysis; Nonsmall cell lung carcinoma

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FOLINIC ACID; HYDROXYUREA; IPROPLATIN; LOMUSTINE; MITOMYCIN C; NAVELBINE; PLATINUM DERIVATIVE; VINDESINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CISPLATIN; CONFIDENCE INTERVALS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0031895251     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980101)82:1<116::AID-CNCR14>3.0.CO;2-5     Document Type: Article

References (56)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
2. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
3. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993;11:1866-72.
4. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-5.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
6. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? another look at the management of non-small-cell lung cancer. J Clin Oncol 1995;13:1904-11.
7. Souhami RL. Chemotherapy in non-small cell lung cancer: time to re-examine our attitudes. Thorax 1996;51:231-2.
8. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
9. Splinter TAW. Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer 1990;26:1093-9.
10. Lau J. Meta-analyst version 0.98. New England Medical Center, Boston, MA, 1996.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
12. Einhorn LH, Williams SD, Stevens EE, Bond WH, Chenoweth L. Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer. Cancer Treat Rep 1982;66:2005-11.
13. Fuks JZ, Egorin MJ, Aisner J, Van Echo DA, Ostrow S, Bachur N, et al. Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma. Cancer Chemother Pharmacol 1983;10:104-8.
14. Luedke DW, Luedke SL, Petruska P, Broun GO, Leavitt J, Schlueter J. A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer. Cancer 1983;51:778-82.
15. Bodey GP, Lagakos SW, Gutierrez AC, Wilson HE, Selawry OS. Therapy of advanced squamous carcinoma of the lung, cyclophosphamide versus "COMB." Cancer 1977;39:1026-31.
16. Hyde L, Wolf J, Phillips R, Mietlowski W. Combined chemotherapy for squamous cell carcinoma of the lung. Chest 1978;73:603-7.
17. Eagan RT, Carr DT, Coles DT, Rubin J, Frytak S. ICRF-159 versus polychemotherapy in non-small cell lung cancer. Cancer Treat Rep 1976;60:947-8.
18. Eagan RT, Ingle JN, Frytak S, Rubin J, Kvols LK, Carr DT, et al. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 1977;61:1339-45.
19. Creech RH, Mehta CR, Cohen M, Donavan M, Sponzo R, Mason BA, et al. Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation 1). Cancer Treat Rep 1981;65:431-8.
20. Britell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S. cis-Dichlorodiammineplatinum (II) alone followed by Adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), Adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 1978;62:1207-10.
21. Anderson G, Payne H. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group. Semin Oncol 1985;12(suppl 2):21-2.
22. Popkin JD, Hong VVK, Cersosimo RJ, Faling U, Now MN, Fofonoff SA: A prospective randomized trial of combination vindesine and cisplatin versus single-agent vindesine in advanced non-small cell lung cancer. Pharmacotherapy 1985;5:20-2.
23. Bang YJ, Lee KH, Kang WK, Park YS, Suh Cl, Kim SY, et al. A prospective randomized study of cisplatin alone vs. PEV (cisplatin, etoposide, vinblastine) chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1993;12:347.
24. Cartei G, Rosa Bian A, Cendron R, Collimedaglia P, Kolarich K, Valentina MD, et al. Evaluation of synergy with cis-platinum (DDP) in non-small cell lung cancer (NSCLC): interim report from a multicentric study. Proc Am Soc Clin Oncol 1988;7:198.
25. Laing AH, Berry RJ, Newman CR, Peto J. Treatment of inoperable carcinoma of bronchus. Lancet 1975;2:1161-4
26. Pannuti F, Lelli G, Cassadio M, Piana E, Di Marco AR. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial. Cancer Treat Rep 1980;64:1131-4.
27. Davis S, Pandya MR, Rambotti P. Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 1980;64:685-8.
28. Lad TE, Nelson RB, Diekamp U, Kukla J, Sarma PR, Larson CS, et al. Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: a randomized trial. CancerTreat Rep 1981;65:973-8.
29. Rudnick SA, Neijstrom E, Capizzi RL, Delaney D, Kirsch M. Randomized phase II comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung. Cancer Treat Rep 1982;66:541-4.
30. Hoffman PC, Newman SB, Golomb HM, Demeester TR, Blough RR, Sovik CA. Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential vs combination chemotherapy. Eur J Cancer Clin Oncol 1983;19:33-8.
31. Elliott JA, Ahmedzai S, Hole D, Dorward AJ, Stevenson RD, Kaye SB, et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 1984;20:1025-32.
32. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 1986;4:1037-43.
33. Sorensen JB, Hansen HH, Dombernowsky P, Borke, Malmberg R, Aabo K, et al. Chemotherapy for adenocarcinoma of the lung (WHO 111): a randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. J Clin Oncol 1987;5:1169-77.
34. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.
35. Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989;7:1087-92.
36. Niell HB, Griffin JP, Hunter RF, Meredith CA, Somes G. Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Med Pediatr Oncol 1989;17:69-75.
37. Rosso R, Salvati F, Ardizzoni A, Curcio CG, Rubagotti A, Belli M, et al. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Cancer 1990;66:130-4.
38. Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non small cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 1990;8:886-91.
39. Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Constanzo F, et al. A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990;26:52-6.
40. Kawahara M, Furuse K, Kodama N, Yamamoto M, Kubota K, Takada M, et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 1991;68:714-9.
41. Vokes EE, Lyss AL, Herndon JE, Cooper B, Perry MC, Vinciguerra V, et al. Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the Cancer and Leukemia Group B. Ann Oncol 1992;3:727-32.
42. Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, et al. A phase II trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 1992;70:2281-7.
43. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993;11:873-8.
44. Le Chevalier T, Brisgand D, Douillard JY, Pujol JP, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European Multicenter Trial Including 612 patients. J Clin Oncol 1994;12:360-7.
45. Depierre A, Chastang Cl, Quoix E, Lebeau B, Blanchon F, Paillot N, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37-42.
46. Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, et al. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 1994;12:353-9.
47. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Lauftnan LR, Baker LH, et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308). Proc Am Soc Clin Oncol 1996;15:374.
48. Splinter Ted AW, Sahmoud T, Festen J, Zandwijk NC, Sorenson S, Clerico M, et al. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14:127-34.
49. Deza GE, Balbiani L, Coppola F, Blajman C, Block J, Giachella O, et al. Phase III study of navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) stage IIIB or IV. Proc Am Soc Clin Oncol 1996;15:394.
50. Masters GA, Vokes EE. Should non-small cell carcinoma of the lung be treated with chemotherapy? pro: chemotherapy is for non-small cell lung cancer. Am J Respir Crit Care Med 1995;151:1285-7.
51. Douglas IS, White SR. Con: therapeutic empiricism-the case against chemotherapy in non-small cell lung cancer. Am J Respir Crit Care Med 1995;151:1288-91.
52. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer. N Engl J Med 1973;288:998-1006.
53. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-22.
54. Marino P, Preatoni A, Cantoni A, Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995;13:1-12.
55. Smith T, Hillner B, Neighbors D, McSorley PA, Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995;13:2166-73.
56. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev 1992;14:154-76.